Antilymphocyte Serum

"Antilymphocyte Serum" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.

Descriptor ID	D000961
MeSH Number(s)	A12.207.152.846.500.203 D12.776.124.486.485.114.573.203 D12.776.124.790.651.114.573.203 D12.776.377.715.548.114.573.203 D20.215.401.203
Concept/Terms	Antilymphocyte Serum Antilymphocyte Serum Antilymphocyte Serums Serum, Antilymphocyte Serums, Antilymphocyte Antilymphocyte Antibodies Antilymphocyte Antibodies Antibodies, Antilymphocyte Antibody, Antilymphocyte Antilymphocyte Antibody Antilymphocyte Globulin Antilymphocyte Globulin Antilymphocyte Globulins Globulin, Antilymphocyte Globulins, Antilymphocyte Pressimmune Pressimmune Antithymoglobulin Antithymoglobulin Antithymoglobulins Antithymocyte Globulin Antithymocyte Globulins Globulin, Antithymocyte Globulins, Antithymocyte Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Lymphocyte Immune Globulin, Anti Thymocyte Globulin Anti-Thymocyte Globulin Anti Thymocyte Globulin Anti-Thymocyte Globulins Globulin, Anti-Thymocyte Globulins, Anti-Thymocyte ATGAM ATGAM Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) Lymphocytotoxic Antibodies Lymphocytotoxic Antibodies Antibodies, Lymphocytotoxic Antibody, Lymphocytotoxic Lymphocytotoxic Antibody Antilymphoblast Globulins Antilymphoblast Globulins Antilymphoblast Globulin Globulin, Antilymphoblast Globulins, Antilymphoblast Antilymphocyte Immunoglobulin Antilymphocyte Immunoglobulin Antilymphocyte Immunoglobulins Immunoglobulin, Antilymphocyte Immunoglobulins, Antilymphocyte

Below are MeSH descriptors whose meaning is more general than "Antilymphocyte Serum".

Anatomy [A]
Fluids and Secretions [A12]
Body Fluids [A12.207]
Blood [A12.207.152]
Serum [A12.207.152.846]
Immune Sera [A12.207.152.846.500]
Antilymphocyte Serum [A12.207.152.846.500.203]
Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Immune Sera [D12.776.124.486.485.114.573]
Antilymphocyte Serum [D12.776.124.486.485.114.573.203]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Immune Sera [D12.776.124.790.651.114.573]
Antilymphocyte Serum [D12.776.124.790.651.114.573.203]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Immune Sera [D12.776.377.715.548.114.573]
Antilymphocyte Serum [D12.776.377.715.548.114.573.203]
Complex Mixtures [D20]
Biological Products [D20.215]
Immune Sera [D20.215.401]
Antilymphocyte Serum [D20.215.401.203]

Below are MeSH descriptors whose meaning is related to "Antilymphocyte Serum".

Below are MeSH descriptors whose meaning is more specific than "Antilymphocyte Serum".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antilymphocyte Serum" by people in this website by year, and whether "Antilymphocyte Serum" was a major or minor topic of these publications.

Bar chart showing 8 publications over 7 distinct years, with a maximum of 2 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2002	1	1
2005	1	1
2012	1	1
2013	1	1
2017	2	2
2018	1	1
2021	1	1

Below are the most recent publications written about "Antilymphocyte Serum" by people in Profiles.

Santos AH, Leghrouz MA, Bueno EP, Andreoni KA. Impact of antibody induction on the outcomes of new onset diabetes after kidney transplantation: a registry analysis. Int Urol Nephrol. 2022 Mar; 54(3):637-646.

View in: PubMed
Varga AN, Johnson D, Sawinski DL, Lim MA, Bloom RD, Abt PL, Goral S, Bleicher M, Levine MH, Naji A, Nazarian S, Porrett P, Trofe-Clark J. Safety and Feasibility of Outpatient Rabbit Antithymocyte Globulin Induction Therapy Administration in Kidney Transplant Recipients. Pharmacotherapy. 2018 06; 38(6):620-627.

View in: PubMed
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011.

View in: PubMed
Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017 Jul; 28(7):2188-2200.

View in: PubMed
Khanmoradi K, Knorr JP, Feyssa EL, Parsikia A, Jawa P, Dinh DB, Campos S, Zaki RF, Ortiz JA. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Exp Clin Transplant. 2013 Jun; 11(3):222-8.

View in: PubMed
Ortiz J, Parsikia A, Mumtaz K, Khanmoradi K, Balasubramanian M, Feyssa E, Campos S, Zaki R, Chewaproug D. Early allograft biopsies performed during delayed graft function may not be necessary under thymoglobulin induction. Exp Clin Transplant. 2012 Jun; 10(3):232-8.

View in: PubMed
Kakhniashvili I, Filicko J, Kraft WK, Flomenberg N. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):609-18.

View in: PubMed
Krasinskas AM, Kreisel D, Acker MA, Bavaria JE, Pochettino A, Kotloff RM, Arcasoy S, Blumenthal N, Kamoun M, Moore JS, Rosengard BR. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002 Apr 27; 73(8):1339-41.

View in: PubMed
Collins NH, Carabasi MH, Bleau S, Jagiello C, Young JW, Castro-Malaspina H, Flomenberg N, Papadopoulos EB, Emanuel D, Gillio A, et al. New technology for the depletion of T cells from soybean lectin agglutinated, HLA-matched bone marrow grafts for leukemia: initial laboratory and clinical results. Prog Clin Biol Res. 1992; 377:427-39.

View in: PubMed
Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990 Aug; 86(2):453-62.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement